The role of molecular xenomonitoring for assessing the impact of Ivermectin, Diethylcarbamazine Citrate and Albendazole triple-drug treatment against lymphatic filariasis: A cross-sectional study in the Kenyan coastal region.

ABSTRACT: Lymphatic Filariasis (LF) is a mosquito-borne disease primarily caused by the filarial parasite Wuchereria bancrofti. The triple-drug therapy of Ivermectin, Diethylcarbamazine Citrate and Albendazole (IDA) has been adopted to accelerate LF elimination of LF as a public health problem, particularly in areas where onchocerciasis is not co-endemic. In Kenya, IDA was administered to endemic communities in Jomvu sub-County (Mombasa) and Lamu County in 2018 and 2019. The impact of IDA was assessed using Molecular Xenomonitoring (MX), which involves detecting W. bancrofti DNA in mosquito pools via quantitative PCR (qPCR). MX surveys were conducted at baseline (2018) and at IDA impact survey 1 (IIS-1) in 2021 after two treatment rounds. Mosquitoes were collected from 30 randomly and 5-9 purposivel

SUBMITTER: Kanyi H 

PROVIDER: S-EPMC12707650 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature